- Completed
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
Updated: Jun 13, 2022
Phase 3 A.R.R.O.W. trial - ARROW
Kd
The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).
Sponsor
Amgen
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02412878
Official Title: A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
First Posted : April 9, 2015
Click here for details on ClinicalTrials.gov
PMID: 29866475
Lancet Oncol;July 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Locations
United States, Arizona
United States, Maryland
United States, New Jersey
United States, New York
United States, Pennsylvania
United States, Texas
Canada, Alberta
Canada, British Columbia
Canada, Newfoundland and Labrador
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Canada
Australia, New South Wales
Australia, Victoria
New Zealand
Europe
United Kingdom
Belgium
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
Italy
Norway
Poland
Romania
Spain
Sweden
Asia
Japan